Daewoong Asset Resilience Ratio
Daewoong asset resilience ratio. Daewoong (003090) has an Asset Resilience Ratio of 0.78% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Daewoong defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Daewoong (2000–2025)
Asset resilience ratio of Daewoong from 2000 to 2025. This chart shows how Daewoong's Asset Resilience Ratio has changed over time. Read debt load of Daewoong for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Daewoong's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 003090 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩26.99 Billion | 0.78% |
| Total Liquid Assets | ₩26.99 Billion | 0.78% |
Asset Resilience Insights
- Limited Liquidity: Daewoong maintains only 0.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Daewoong Industry Peers by Asset Resilience Ratio
Compare Daewoong's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Daewoong Asset Resilience Ratio by Year (2000–2025)
Daewoong asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Daewoong.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.92% | ₩29.88 Billion ≈ $20.25 Million |
₩3.23 Trillion ≈ $2.19 Billion |
-1.74pp |
| 2024-12-31 | 2.67% | ₩72.62 Billion ≈ $49.21 Million |
₩2.72 Trillion ≈ $1.84 Billion |
-1.80pp |
| 2023-12-31 | 4.47% | ₩105.48 Billion ≈ $71.48 Million |
₩2.36 Trillion ≈ $1.60 Billion |
-4.62pp |
| 2022-12-31 | 9.09% | ₩196.30 Billion ≈ $133.03 Million |
₩2.16 Trillion ≈ $1.46 Billion |
-4.52pp |
| 2021-12-31 | 13.61% | ₩263.22 Billion ≈ $178.38 Million |
₩1.93 Trillion ≈ $1.31 Billion |
+3.97pp |
| 2020-12-31 | 9.64% | ₩177.20 Billion ≈ $120.09 Million |
₩1.84 Trillion ≈ $1.25 Billion |
-2.08pp |
| 2019-12-31 | 11.72% | ₩195.58 Billion ≈ $132.54 Million |
₩1.67 Trillion ≈ $1.13 Billion |
+3.18pp |
| 2018-12-31 | 8.54% | ₩135.99 Billion ≈ $92.16 Million |
₩1.59 Trillion ≈ $1.08 Billion |
+0.09pp |
| 2017-12-31 | 8.45% | ₩130.86 Billion ≈ $88.68 Million |
₩1.55 Trillion ≈ $1.05 Billion |
-2.83pp |
| 2016-12-31 | 11.28% | ₩165.53 Billion ≈ $112.18 Million |
₩1.47 Trillion ≈ $994.36 Million |
-0.98pp |
| 2015-12-31 | 12.26% | ₩152.27 Billion ≈ $103.19 Million |
₩1.24 Trillion ≈ $841.89 Million |
-4.02pp |
| 2014-12-31 | 16.28% | ₩164.50 Billion ≈ $111.48 Million |
₩1.01 Trillion ≈ $684.96 Million |
+9.62pp |
| 2013-12-31 | 6.65% | ₩59.77 Billion ≈ $40.50 Million |
₩898.47 Billion ≈ $608.88 Million |
+4.71pp |
| 2012-12-31 | 1.94% | ₩9.89 Billion ≈ $6.70 Million |
₩509.22 Billion ≈ $345.09 Million |
-0.52pp |
| 2011-12-31 | 2.46% | ₩11.73 Billion ≈ $7.95 Million |
₩476.95 Billion ≈ $323.23 Million |
+0.44pp |
| 2010-12-31 | 2.02% | ₩15.53 Billion ≈ $10.53 Million |
₩770.12 Billion ≈ $521.90 Million |
-11.70pp |
| 2009-12-31 | 13.72% | ₩96.91 Billion ≈ $65.67 Million |
₩706.44 Billion ≈ $478.74 Million |
+8.10pp |
| 2008-12-31 | 5.62% | ₩38.40 Billion ≈ $26.03 Million |
₩683.79 Billion ≈ $463.39 Million |
+0.93pp |
| 2007-12-31 | 4.69% | ₩25.30 Billion ≈ $17.15 Million |
₩539.93 Billion ≈ $365.91 Million |
+0.49pp |
| 2006-12-31 | 4.19% | ₩18.97 Billion ≈ $12.85 Million |
₩452.46 Billion ≈ $306.62 Million |
-0.65pp |
| 2005-12-31 | 4.84% | ₩18.73 Billion ≈ $12.70 Million |
₩387.05 Billion ≈ $262.30 Million |
-1.52pp |
| 2004-12-31 | 6.36% | ₩21.58 Billion ≈ $14.62 Million |
₩339.21 Billion ≈ $229.88 Million |
+3.32pp |
| 2003-12-31 | 3.04% | ₩9.69 Billion ≈ $6.56 Million |
₩318.37 Billion ≈ $215.76 Million |
-3.88pp |
| 2002-12-31 | 6.92% | ₩22.03 Billion ≈ $14.93 Million |
₩318.26 Billion ≈ $215.68 Million |
-6.52pp |
| 2001-12-31 | 13.44% | ₩46.16 Billion ≈ $31.29 Million |
₩343.38 Billion ≈ $232.70 Million |
-2.22pp |
| 2000-12-31 | 15.67% | ₩53.29 Billion ≈ $36.12 Million |
₩340.15 Billion ≈ $230.52 Million |
-- |
About Daewoong
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Phar… Read more